 21. Patients who are sexually active and unwilling to use a medically acceptable method of contraception e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males during the trial and for at least 12 months after end of active therapy 